---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-006233"
form_type: "8-K"
ticker: "URGN"
cik: "0001668243"
company_name: "UroGen Pharma Ltd."
filed_at: "2026-03-02T23:59:59+00:00"
generated_at: "2026-05-15T22:40:42.144244+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# UroGen reports FY2025 net loss $153.5M; ZUSDURI launch net sales $15.8M; refinances debt at 8.25%

## Summary
- FY2025 revenue $109.8M (+21% YoY); JELMYTO net sales $94M (underlying demand +7%).
- ZUSDURI net sales $15.8M in initial launch; 838 activated sites, 102 unique prescribers as of Dec 31, 2025.
- Permanent J Code (J9282) effective Jan 1, 2026; launch acceleration expected.
- Refinanced existing term loan: $200M funded at 8.25% fixed, new $50M tranche available until June 2027.
- 2026 guidance: JELMYTO net sales $97-101M; total operating expenses $240-250M.

## SEC filing metadata
- accession: 0001437749-26-006233
- form_type: 8-K
- ticker: URGN
- cik: 0001668243
- company_name: UroGen Pharma Ltd.
- filed_at: 2026-03-02T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1668243/000143774926006233/0001437749-26-006233-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1668243/000143774926006233/urgn20260226_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-006233
- JSON: https://secwatch.observer/filing/0001437749-26-006233.json
- Plain text: https://secwatch.observer/filing/0001437749-26-006233.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.